Mark E Jonas

Suggest Changes
Learn More
BACKGROUND Many patients with primary biliary cholangitis have an inadequate response to first-line therapy with ursodeoxycholic acid. Seladelpar is a potent, selective agonist for the peroxisome(More)
  • 1